YF17D‐based vaccines – standing on the shoulders of a giant
European Journal of Immunology · 2024
DOI: 10.1002/eji.202250133 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Lorena Sanchez-Felipe und 4 weiteren Autor:innen. Beteiligte Einrichtung: KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Molecular Vaccinology and Vaccine Discovery, Leuven, Belgium. Hauptthemen laut MEDLINE: Yellow Fever Vaccine, Yellow fever virus, Vaccines, Attenuated. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 230 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Flemish Research Foundation (FWO) Excellence of Science (EOS) program, European Union's Horizon 2020 research and innovation program, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Live‐attenuated yellow fever vaccine (YF17D) was developed in the 1930s as the first ever empirically derived human vaccine. Ninety years later, it is still a benchmark for vaccines made today. YF17D triggers a particularly broad and polyfunctional response engaging multiple arms of innate, humoral and cellular immunity. This unique immunogenicity translates into an extraordinary vaccine efficacy and outstanding longevity of protection, possibly by single‐dose immunization. More recently, progress in molecular virology and synthetic biology allowed engineering of YF17D as a powerful vector and promising platform for the development of novel recombinant live vaccines, including two licensed vaccines against Japanese encephalitis and dengue, even in paediatric use. Likewise, numerous chimeric and transgenic preclinical candidates have been described. These include prophylactic vaccines against emerging viral infections (e.g. Lassa, Zika and SARS‐CoV‐2) and parasitic diseases (e.g. malaria), as well as therapeutic applications targeting persistent infections (e.g. HIV and chronic hepatitis), and cancer. Efforts to overcome historical safety concerns and manufacturing challenges are ongoing and pave the way for wider use of YF17D‐based vaccines. In this review, we summarize recent insights regarding YF17D as vaccine platform, and how YF17D‐based vaccines may complement as well as differentiate from other emerging modalities in response to unmet medical needs and for pandemic preparedness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Molecular Vaccinology and Vaccine Discovery, Leuven, Belgium.
ORCID-Profile: Lorena Sanchez-Felipe, Yeranddy A Alpizar, Ji Ma, Lotte Coelmont, Kai Dallmeier
Förderung
- Flemish Research Foundation (FWO) Excellence of Science (EOS) program
- European Union's Horizon 2020 research and innovation program
- Bill and Melinda Gates Foundation
- European Health Emergency Preparedness and Response Authority (HERA)
Zitieren
APA
Sanchez-Felipe, L., Alpizar, Y. A., Ma, J., Coelmont, L., & Dallmeier, K. (2024). YF17D‐based vaccines – standing on the shoulders of a giant. European Journal of Immunology. https://doi.org/10.1002/eji.202250133
Vancouver
Sanchez-Felipe L, Alpizar YA, Ma J, Coelmont L, Dallmeier K. YF17D‐based vaccines – standing on the shoulders of a giant. European Journal of Immunology. 2024. doi:10.1002/eji.202250133
BibTeX
@article{SanchezFelipe2024,
author = {Sanchez-Felipe, Lorena and Alpizar, Yeranddy A and Ma, Ji and Coelmont, Lotte and Dallmeier, Kai},
title = {YF17D‐based vaccines – standing on the shoulders of a giant},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202250133}
}
EUVIMED